NovoCure Ltd — Director's Dealing 2021

Nov 29, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2021-11-26

Reporting Person: Danziger Asaf (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-26	Ordinary Shares	P	3870	$102.36	Acquired	12172	Direct
2021-11-26	Ordinary Shares	P	1000	$103.37	Acquired	13172	Direct
2021-11-26	Ordinary Shares	P	104	$96.50	Acquired	13276	Direct

Footnotes

F1: On November 26, 2021, Mr. Danziger purchased 3,870 shares in multiple trades at prices ranging from $102.00 to $102.60. The price reported above reflects the weighted average purchase price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.